Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Dec;27(12):2837-2840.
doi: 10.1002/ejhf.3699. Epub 2025 May 19.

Safety and tolerability of a 5 mg starting dose of vericiguat among patients with heart failure: The VELOCITY study

Stephen J Greene  1   2 , Stefano Corda  3 , Ciaran J McMullan  4 , Giovanni Palombo  3 , Christina Schooss  5 , Vanja Vlajnic  6 , Katrin Walkamp  7 , Michele Senni  8 ; on behalf of the VELOCITY investigators
Affiliations

Safety and tolerability of a 5 mg starting dose of vericiguat among patients with heart failure: The VELOCITY study

Stephen J Greene et al. Eur J Heart Fail. 2025 Dec.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Proportion of vericiguat‐treated patients achieving primary tolerability endpoint. Patients in VELOCITY initiated on vericiguat 5 mg daily were compared with patients in VICTORIA initiated on vericiguat 2.5 mg daily. The primary endpoint was completion of 2‐week study period with maximum 1‐day interruption and without symptomatic hypotension of moderate to severe intensity. The sensitivity analysis of the primary endpoint was completion of 2‐week study period with maximum 2 days of interruption and without symptomatic hypotension of moderate to severe intensity. WHF, worsening heart failure.
See this image and copyright information in PMC

References

    1. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al.; ESC Scientific Document Group . 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC).With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2022;24:4–131. 10.1002/ejhf.2333 - DOI - PubMed
    1. Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol 2022;79:e263–e421. 10.1016/j.jacc.2021.12.012 - DOI - PubMed
    1. Greene SJ, Fonarow GC, DeVore AD, Sharma PP, Vaduganathan M, Albert NM, et al. Titration of medical therapy for heart failure with reduced ejection fraction. J Am Coll Cardiol 2019;73:2365–2383. 10.1016/j.jacc.2019.02.015 - DOI - PMC - PubMed
    1. Greene SJ, Ezekowitz JA, Anstrom KJ, Demyanenko V, Givertz MM, Pina IL, et al. Medical therapy during hospitalization for heart failure with reduced ejection fraction: The VICTORIA registry. J Card Fail 2022;28:1063–1077. 10.1016/j.cardfail.2022.02.011 - DOI - PubMed
    1. Greene SJ, Bash LD, Tebbs KW, Hancock LN, Barlow SG, Coyle CR. Physician‐reported reasons for not initiating guideline‐directed medical therapy for heart failure. JACC Heart Fail 2024;12:2120–2122. 10.1016/j.jchf.2024.08.002 - DOI - PubMed